Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), today announced that Walter Klemp, Chairman and Chief Executive Officer of Moleculin, participated in a Virtual Investor "What This Means" segment.

For the segment, Chairman and CEO Wally Klemp discusses the positive preliminary unblinded efficacy results from the first 45 patients enrolled in Part A of the pivotal Phase 2/3 MIRACLE trial evaluating Annamycin in relapsed or refractory acute myeloid leukemia (R/R AML). During the conversation, Mr. Klemp provides his perspective on the significance of the early efficacy trends observed across both Annamycin treatment arms, summarizes the key data, and discusses the commercial opportunity, including insights from the Company's recent market research assessing the potential addressable market for Annamycin if approved.